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Major advances have been made during the past 4 years in understanding the pathophysiology of aldosterone 
production in patients with primary aldosteronism (PA).1 The 
breakthrough was the identification of somatic mutations in 
the potassium channel GIRK4 (encoded by KCNJ5) in aldo-
sterone-producing adenomas (APAs)2 and the contemporane-
ous discovery, by the same authors, of a germline mutation 
responsible for familial hyperaldosteronism type III.2 This was 
followed by the identification of further somatic mutations in 
APAs in 2 ATPases (Na+/K+-ATPase 1 and Ca2+-ATPase 3, 
encoded by ATP1A1 and ATP2B3, respectively) and in a sub-
unit of an L-type voltage-gated Ca2+-channel, Cav1.3 (encoded 
by CACNA1D).1–5
The zona glomerulosa cells of the adrenal cortex display a 
high resting outward potassium current through the GIRK4 
potassium channel that contributes to the hyperpolarization of 
the cell membrane. Most of the GIRK4 mutations identified 
in APA are located in or within close proximity to the selec-
tivity filter of the K+ channel and result in the indiscriminate 
conductance of Na+ that depolarizes the cell membrane and 
causes the opening of voltage-gated Ca2+ channels. The resul-
tant Ca2+ influx and activation of the Ca2+ signaling pathway 
results in the activation of CYP11B2 gene transcription and an 
increase in aldosterone biosynthesis.6
The other somatic APA mutations in ATP1A1, ATP2B3, 
and CACNA1D are also predicted, or have been demonstrated, 
to cause an increase in aldosterone production via the activa-
tion of the Ca2+ signaling pathway although the mechanism at 
source that leads to Ca2+ influx differs.6
At present, the origin of the increased cell proliferation 
in the adenomas is unknown and is not accounted for by the 
increase in intracellular Ca2+ induced by the APA mutations.7
In the present issue of Hypertension, Zheng et al8 report a 
strikingly high prevalence (77%) of KCNJ5 somatic mutations 
in 168 APA removed from Chinese patients. Consistent with 
previous reports, mutations in the other genes were rarer, 4 in 
ATP1A1 (2.8%) and 1 each in ATP2B3 and CACNA1D. This in 
agreement with other reports from Japanese patients in which 
KCNJ5 mutations were present in 65% to 69% of APAs,9,10 
indicating that KCNJ5 mutations are the most frequent genetic 
cause of excessive aldosterone production in Eastern Asian 
patients with APA (Figure [A]).
These results display some differences and similarities with 
those in a study of somatic APA mutations in white patients.11 
The most intriguing common feature is the predominance of 
somatic KCNJ5 mutations in women, which has been con-
sistently reported in white cohorts and now in Chinese and 
Japanese patients.6,8–12 The underlying mechanism responsible 
for this distinction is unknown, a difference in the pheno-
type between sexes has been reported in the leak K+ channel 
TASK1 knockout animal model, in which only female adults 
display hyperaldosteronism, whereas males are unaffected 
and seem to be protected by the androgen-regulated compen-
satory expression of TASK3 channels.7
Zheng et al8 also reported an apparently more severe bio-
chemical phenotype (higher aldosterone:renin ratio and lower 
potassium although not a higher lateralization index at adrenal 
vein sampling [AVS]) compared with patients without muta-
tions in KCNJ5, CACNA1D, ATP1A1, and ATP2B3. A similar 
biochemically more severe phenotype has been observed in 
some but not in all studies in whites and in particular was not 
observed in the largest study in European patients.11 It should 
be considered that the no-mutation group could be heteroge-
neous in that it almost certainly comprises patients with as 
yet unidentified genes carrying somatic APA mutations, as 
well as some patients in which adrenalectomy was decided on 
the basis of the computed tomographic scanning alone with-
out performing AVS or using AVS criteria that are not strict 
enough to ensure the removal of an APA13 and result in the 
removal of 1 adrenal with a nodule in the context of a bilateral 
disease. If this is the case, the mutated group will always dis-
play a more severe clinical and biochemical phenotype com-
pared with the no-mutation group. In the study by Zheng et 
al,8 less than half of the patients underwent AVS; however, 
the proportion of KCNJ5 mutations was not significantly dif-
ferent in the group operated on the basis of the computed 
tomographic scanning or after AVS, a finding also observed 
in the Paris cohort.11 Therefore, a major selection bias should 
not have interfered with the findings of the present study. By 
contrast, the use of AVS in a minority of patients with PA 
could have been responsible for the relatively low prevalence 
of CACNA1D mutations in this Chinese cohort. In fact, APAs 
harboring CACNA1D mutations are associated with smaller 
nodule dimensions5,11 and, therefore, it is conceivable that 
a lower proportion of patients carrying these mutations are 
observed in cohorts where AVS is not performed in all patients 
with PA and are adrenalectomized relying on imaging alone, 
a strategy that could miss a relevant proportion of APAs with 
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CACNA1D mutations. It should be emphasized that, at pres-
ent, the phenotype presentation of patients with or without 
mutations in the above genes do not display any character-
istics that are sensitive or specific enough to allow the detec-
tion of a patient with a somatic mutation only by relying on a 
specific clinical or biochemical picture. Furthermore, even if 
specific peripheral biomarkers should become available, AVS 
would still be required to determine the correct side for the 
adrenalectomy in those patients.
The interest in the role of KCNJ5 mutations in PA has been 
heightened further by the recent discovery of 3 novel germline 
mutations (p.Arg52His, p.Glu246Lys, and p.Gly247Arg) and a 
rare nonsynonymous single nucleotide polymorphism respon-
sible for the substitution p.Glu282Gln, in a cohort of patients 
with sporadic PA.14 Interestingly, the substitutions, with the 
exception of the 247 mutation that had no effect, were associ-
ated with an alteration of GIRK4 function in vitro resulting 
in a loss of ion selectivity causing Na+-influx and stimulation 
of aldosterone secretion.14 Therefore, germline KCNJ5 muta-
tions are not only responsible for the severe familial hyper-
aldosteronism type III but are also present in a significant 
proportion (≈6%) of patients with sporadic PA (Figure [B]). 
These findings also demonstrated that even mutations located 
at some distance from the selectivity filter display functional 
effects that alter GIRK4 function and determine the promis-
cuous entry of sodium through GIRK4 into cells, ultimately 
resulting in increased aldosterone secretion.
Recent years have shed light on the mechanisms respon-
sible for the increased aldosterone production in APA and in 
familial hyperaldosteronism type III, but at present we are still 
largely unaware of the alterations that cause the increased cell 
proliferation (or reduced apoptosis) in APA and in bilateral 
adrenal hyperplasia.1 It seems conceivable that multiple hits 
on the adrenal cortex are necessary to obtain the final clinical 
and pathological picture because mutations in APAs are often 
demonstrated in a background of adrenal hyperplasia associ-
ated with the overexpression of progenitor/stem cell markers.7 
Furthermore, APAs are often associated with multiple nodules 
in the cortex indicating that the formation of a nodule is inde-
pendent from the appearance of a mutation that confers the 
secretory activity to the nodule.15
Interestingly, a recent study investigated the association of 
KCNJ5 single nucleotide polymorphisms and PA in Chinese 
patients; one of the polymorphisms, located in the 3′untrans-
lated region, was associated with PA in male patients.16 The 
functional effect of this polymorphism is unknown; however, 
an effect on mRNA stability or processing is not expected 
to cause hyperaldosteronism because variations in KCNJ5 
expression (including silencing and overexpression) do not 
result in major changes in aldosterone secretion and, there-
fore, the significance of this association needs to be explored 
more in depth and confirmed in a different population.
An advance in understanding the role of KCNJ5 in aldo-
sterone hypersecretion has also been defined from pharmaco-
logical evidence: mutated GIRK4 channels are less sensitive 
to tertiapin-Q, a selective inhibitor of wild-type GIRK4. 
Furthermore, mutated GIRK4 activity is blocked by the epi-
thelial sodium channel inhibitor amiloride, and even more 
potently by the phenylalkylamine L-type calcium channel 
blocker verapamil. By contrast, the dihydropiridine calcium 
channel blocker nifedipine is a weak blocker of the mutated 
channel.17 This information will potentially stimulate the 
search or design of new and selective blockers of mutated 
GIRK4 channels that are predicted to be effective in patients 
with familial hyperaldosteronism type III and in a significant 
subset of patients with sporadic PA. The effects of verapamil 
on blood pressure and aldosterone levels in patients carrying 
KCNJ5 mutations could be because of a dual effect of block-
ing the mutated GIRK4 channel in addition to the voltage-
gated calcium channel activated by the cell depolarization 
subsequent to sodium entry through the GIRK4 channel. This 
should be taken into account because verapamil is considered 
to be neutral on aldosterone levels and is, therefore, consid-
ered one of the drugs of choice during PA diagnostic work-up. 
Figure. A. Relative frequency of 
mutations in KCNJ5, ATP1A1, ATP2B3, 
and CACNA1D in Eastern Asia and white 
patients. B, Somatic and germline KCNJ5 
mutations demonstrated in patients with 
aldosterone-producing adenoma, in 
familial hyperaldosteronism (FH)-III and in 
sporadic primary aldosteronism (PA).
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By contrast, verapamil has the potential to reduce aldoste-
rone production resulting in a negative screening test or in a 
reduced lateralization index during AVS.
In conclusion, mutations in KCNJ5 are the most frequent 
known alterations in patients with PA: drugs specifically 
blocking the mutated GIRK4 channel are expected to be effec-
tive in a large percentage of patients with PA.
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